Acute lymphoblastic leukaemia: trials for referral
617 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Acute lymphoblastic leukaemia·What we know·Glossary·Tumour board sheet
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 617 open trials.
No phase0 sites
Not yet recruiting
NCT07921550
Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Pre-treatment window Registry sentence: “Newly diagnosed, untreated (except prednisone/hydroxyurea) Ph-negative ALL by morphology and immunophenotype.”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07572136
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07790913
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
St. Jude Children's Research Hospital
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingGermany
NCT07108868
A Phase I Dose Finding Study of MB-CART2219.1
University Hospital Tuebingen
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07923071
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Syndax Pharmaceuticals
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07869368
BLinatumomab and iNKT in Relapsed B-Cell ALL
UNC Lineberger Comprehensive Cancer Center
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 39 sites
RecruitingGermany, Spain, Netherlands, United States
NCT07223021
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingChina
NCT07919470
Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
Peking University People's Hospital
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT07239323
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Chongqing Precision Biotech Co., Ltd
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 210 sites
Not yet recruitingSpain
NCT07862946
Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia
PETHEMA Foundation
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07914166
Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
City of Hope Medical Center
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07040982
Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
City of Hope Medical Center
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 3460 sites
RecruitingCanada, United States
NCT03150693
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT02390752
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Cancer Institute (NCI)
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07891468
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
University of Pennsylvania
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingChina
NCT05995028
Universal 4SCAR7U Targeting CD7-positive Malignancies
Shenzhen Geno-Immune Medical Institute
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
Not yet recruitingChina
NCT04016129
CAR-T Immunotherapy Targeting CD19- ALL
Shenzhen Geno-Immune Medical Institute
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
Not yet recruitingChina
NCT04033302
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Shenzhen Geno-Immune Medical Institute
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06904066
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Cancer Institute (NCI)
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT02727803
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 12 sites
RecruitingChina
NCT07910708
GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/22 sites
RecruitingUnited States
NCT06308588
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Pre-treatment window Registry sentence: “a) Participants ≥18 years of age with previously untreated or minimally pretreated Ph-positive ALL who are not suitable candidates for intensive chemotherapy.”
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/272 sites
RecruitingAustralia, Belgium, Brazil, Canada, Chile, Colombia
NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme LLC
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 2/335 sites
RecruitingCanada, Denmark, Spain, France, Greece, Israel
NCT07570173
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Merck Sharp & Dohme LLC
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 1/211 sites
RecruitingChina
NCT05579132
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
MSD R&D (China) Co., Ltd.
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 1/24 sites
RecruitingUnited States
NCT05322850
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06287944
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 119 sites
RecruitingUnited States
NCT04301076
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Patients must have histologically or cytologically confirmed CD2+, CD3+, or CD4+ acute, lymphoma or poor-risk chronic subtypes of ATLL including previously untreated or previously treated individuals who have received no more than 1 previous cycle of EPOCH, cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), or cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE)”
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07254793
Prophylactic DLI-X for Leukemia Relapse After HCT
University of Arizona
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 14 sites
RecruitingChina
NCT04807881
Phase Ib Clinical Study of Keynatinib
Medolution Ltd.
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States167 open trials
- China132 open trials
- Spain27 open trials
- Italy25 open trials
- Germany24 open trials
- France24 open trials
- Canada23 open trials
- United Kingdom19 open trials
- Australia16 open trials
- Denmark15 open trials
- South Korea14 open trials
- Netherlands13 open trials
- Belgium13 open trials
- Czechia12 open trials
- Sweden11 open trials
- Austria11 open trials
- Israel10 open trials
- Finland9 open trials
- Norway9 open trials
- Japan8 open trials
- Poland8 open trials
- Switzerland8 open trials
- Taiwan7 open trials
- Brazil7 open trials
- Hungary7 open trials
- Greece6 open trials
- Hong Kong6 open trials
- Türkiye5 open trials
- Portugal5 open trials
- Mexico5 open trials
- Ireland5 open trials
- Slovakia4 open trials
- Puerto Rico4 open trials
- Romania4 open trials
- Russia4 open trials
- New Zealand3 open trials
- Malaysia3 open trials
- Slovenia2 open trials
- Saudi Arabia2 open trials
- Belarus2 open trials
- Lithuania2 open trials
- Bulgaria2 open trials
- Singapore2 open trials
- Colombia1 open trial
- Chile1 open trial
- Réunion1 open trial
- Croatia1 open trial
- Estonia1 open trial
- Iceland1 open trial
- Jordan1 open trial
- Pakistan1 open trial
- Lebanon1 open trial
- Argentina1 open trial
- Vietnam1 open trial
- Thailand1 open trial
- Indonesia1 open trial
- India1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
32 trials · 21 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
New in the registry
Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
NCT07919470 · No phase · China
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051 · Phase 1 · Germany
Source: ClinicalTrials.govClosed for recruitment
NCT07134088 · Phase 1/2 · France, Italy, Japan, Netherlands, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496 · Phase 1 · Belgium, China, Spain, France, Israel, Italy
Source: ClinicalTrials.govClosed for recruitment
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
NCT05306301 · Phase 2 · Italy
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05182385 · Phase 1/2 · Germany
Source: ClinicalTrials.govPhase changed: Phase 3 → Phase 4
NCT04877522 · Phase 4 · Argentina, Austria, Bulgaria, Brazil, Canada, China
Source: ClinicalTrials.govPhase changed: Phase 2/3 → Phase 3
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576 · Phase 3 · Belgium, Germany, Denmark, Estonia, Spain, Finland
Source: ClinicalTrials.govOpened for recruitment
NCT04150497 · Phase 1/2 · Spain, France, Italy, United States
Source: ClinicalTrials.govClosed for recruitment
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336 · Phase 1/2 · Belgium, Canada, Germany, Spain, France, Italy
Source: ClinicalTrials.govOpened for recruitment
NCT03643276 · Phase 3 · Austria, Australia, Switzerland, Czechia, Germany, Israel
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513 · Phase 1/2 · Germany, Spain, France, United Kingdom, Italy, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT03541083 · Phase 2 · Belgium, Netherlands
Source: ClinicalTrials.govOpened for recruitment
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03590171 · Phase 2 · Austria, Australia, Belgium, Czechia, Germany, Denmark
Source: ClinicalTrials.govOpened for recruitment
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
NCT05306301 · Phase 2 · Italy
Source: ClinicalTrials.govClosed for recruitment
NCT04150497 · Phase 1/2 · Spain, France, Italy, United States
Source: ClinicalTrials.gov
Show more
Closed for recruitment
NCT03643276 · Phase 3 · Austria, Australia, Switzerland, Czechia, Germany, Israel
Source: ClinicalTrials.govClosed for recruitment
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03590171 · Phase 2 · Austria, Australia, Belgium, Czechia, Germany, Denmark
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Not yet recruiting
NCT07134088 · Phase 1/2 · France, Italy, Japan, Netherlands, United States
Source: ClinicalTrials.govOpened for recruitment
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336 · Phase 1/2 · Belgium, Canada, Germany, Spain, France, Italy
Source: ClinicalTrials.govPhase changed: No phase → Phase 1/2
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NCT06508775 · Phase 1/2 · Germany
Source: ClinicalTrials.govPhase changed: No phase → Phase 1
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051 · Phase 1 · Germany
Source: ClinicalTrials.gov
New reviews, guidelines and randomised trials in PubMed
Systematic review
A systematic review on the possible role of microRNA-155 in cancer treatment.
Frontiers in pharmacology · PubMed
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 30 Sept 2026
Completed307 participants
NCT04635384
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
Phase 2Ended 22 Sept 2026
Withdrawn before start0 participants
NCT06210750
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
Reason given: Other - Protocol moved to Disapproved
Phase 4Ended 13 Sept 2026
Stopped early49 participants
NCT07320534
Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
Reason given: Interim analysis showed no significant benefit of levofloxacin. Prolonged antibiotic use may increase adverse effects and resistance. Limited funding and the approaching end of the study period also supported early termination.
Phase 2Ended 8 Sept 2026
Completed93 participants
NCT04233346
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
No phaseEnded 14 Aug 2026
Completed70 participants
NCT07882069
Effect of ACTIVE-Care on Cancer-Related Fatigue, Hope, and Psychological Resilience in Adolescents With Acute Lymphoblastic Leukemia
Phase 1/2Ended 14 Aug 2026
Stopped early58 participants
NCT02392572
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Reason given: \<75% participants
Phase 1Ended 13 Aug 2026
Withdrawn before start0 participants
NCT05168748
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
Reason given: Sponsor's decision
Phase 1Ended 31 Jul 2026
Stopped early10 participants
NCT05262673
NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
No reason given in the registry.
Phase 1Ended 31 Jul 2026
Stopped early10 participants
NCT05277753
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
No reason given in the registry.
Phase 1/2Ended 31 Jul 2026
Stopped early100 participants
NCT04430530
4SCAR-T Therapy Post CD19-targeted Immunotherapy
No reason given in the registry.
Phase 1Ended 21 Jul 2026
Completed6 participants
NCT07295951
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Phase 1Ended 1 Jul 2026
Stopped early4 participants
NCT07556757
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
Reason given: Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug
No phaseEnded 2 Jun 2026
Completed35 participants
NCT05230004
Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate Growth
Phase 1Ended 1 Jun 2026
Withdrawn before start0 participants
NCT03939585
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Reason given: Lack of funding
No phaseEnded 26 May 2026
No phaseEnded 14 May 2026
Stopped early200 participants
NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Reason given: No longer a research question to answer.
Phase 1/2Ended 5 May 2026
Stopped early53 participants
NCT03808610
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
Reason given: \<75% participation
Phase 1Ended 27 Apr 2026
Withdrawn before start0 participants
NCT07428486
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
Reason given: PI requested
Phase 2Ended 21 Apr 2026
Stopped early4 participants
NCT05268003
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Reason given: \< 75% participation
Phase 2Ended 21 Apr 2026
Completed124 participants
2024-517389-40-00
Efficacy and safety of obinutuzumab versus rituximab in combination with chemotherapy for adult patients with newly diagnosed CD20-positive acute lymphoblastic leukemia
Show more
Phase 2Ended 21 Apr 2026
Stopped early49 participants
NCT04920968
Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"
Reason given: Following the recommendation of the Data Monitoring Committee (DMC), based on the results of the interim analysis, the Sponsor has decided to terminate the study prematurely
Phase 3Ended 31 Mar 2026
Completed570 participants
NCT01503632
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Phase 3Ended 31 Mar 2026
No phaseEnded 31 Mar 2026
Completed150 participants
NCT05750706
Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative
Phase 3Ended 31 Mar 2026
Phase 1/2Ended 25 Mar 2026
No phaseEnded 15 Mar 2026
Completed27 participants
NCT06794762
Effects of Core Stabilization Exercises in Children With Acute Lymphoblastic Leukemia
Phase 4Ended 13 Mar 2026
Completed76 participants
NCT06035757
The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
Phase 2Ended 3 Mar 2026
Completed171 participants
NCT02723994
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Phase 1Ended 13 Feb 2026
Completed25 participants
NCT00641381
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Phase 1Ended 4 Feb 2026
Phase 2Ended 2 Feb 2026
No phaseEnded 26 Jan 2026
Phase 1Ended 21 Jan 2026
Completed86 participants
NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Phase 2Ended 20 Jan 2026
Phase 2Ended 13 Jan 2026
No phaseEnded 12 Jan 2026
Completed8 participants
NCT04940468
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
Phase 1/2Ended 7 Jan 2026
Phase 3Ended 7 Jan 2026
Withdrawn before start0 participants
NCT03628053
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Reason given: Novartis is no longer pursuing this study because of planned investigation of novel CAR-T therapies in this patient population.
No phaseEnded 1 Jan 2026
Completed18 participants
NCT05296096
PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS
Phase 1/2Ended Dec 2025
Withdrawn before start0 participants
NCT05895201
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Reason given: PI has left IU with no plan to initiate study at IU
No phaseEnded 31 Dec 2025
No phaseEnded 31 Dec 2025
No phaseEnded 23 Dec 2025
Completed583 participants
NCT05818644
Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
Phase 1Ended 19 Dec 2025
Phase 2Ended 19 Dec 2025
Stopped early40 participants
NCT03156790
PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia
Reason given: Early termination
No phaseEnded 17 Dec 2025
Phase 2Ended 15 Dec 2025
Phase 1Ended 4 Dec 2025
No phaseEnded 1 Dec 2025
Completed10 participants
NCT05969002
Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias
No phaseEnded 30 Nov 2025
Phase 1/2Ended 17 Nov 2025
Phase 4Ended 6 Nov 2025
Completed44 participants
NCT05687032
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1/2Ended 6 Nov 2025
Stopped early37 participants
NCT03698552
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Reason given: \<75% participation
Phase 1/2Ended 27 Oct 2025
Completed161 participants
NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
No phaseEnded 27 Oct 2025
Completed166 participants
NCT04321200
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
No phaseEnded 26 Oct 2025
Completed621 participants
NCT05774990
Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment
Phase 3Ended 17 Oct 2025
Completed21 participants
NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
No phaseEnded 15 Oct 2025
Phase 2Ended 13 Oct 2025
Stopped early15 participants
NCT03856216
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
Reason given: \<75% participation
- Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. · Journal of the National Comprehensive Cancer Network : JNCCN, 2025
Not medical advice. fetched 9 Nov 2026